US87808K1060 - Common Stock
TCR2 THERAPEUTICS INC
NASDAQ:TCRR (5/31/2023, 7:00:02 PM)
After market: 1.53 +0.05 (+3.38%)1.48
-0.09 (-5.73%)
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company’s TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
TCR2 THERAPEUTICS INC
100 Binney St
Cambridge MASSACHUSETTS 02142
P: 16179495200.0
CEO: Garry E. Menzel
Employees: 58
Website: https://www.tcr2.com/
Adaptimmune (ADAP) said that it has completed its planned merger with fellow T-cell therapy developer TCR2 (TCRR). Read more here.
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (TCR2 or the Company), a clinical-stage cell therapy company...
CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel...
/PRNewswire/ -- The "Pancreatic Cancer - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Pancreatic Cancer-...
Here you can normally see the latest stock twits on TCRR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: